Maturation matters: Importance of maturation for antitumor immunity of dendritic cell vaccines

被引：13

作者：

Adams, S ^{[1
]}

O'Neill, D ^{[1
]}

Bhardwaj, N ^{[1
]}

机构：

[1] NYU, Inst Canc, Sch Med, Tumor Vaccine Program, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 18期

关键词：

D O I：

10.1200/JCO.2004.99.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3834 / 3835

页数：2

共 5 条

[1] Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
Dhodapkar, MV
Steinman, RM
Krasovsky, J
Munz, C
Bhardwaj, N
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (02) : 233 - 238
[2] A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection
Jonuleit, H
Giesecke-Tuettenberg, A
Tüting, T
Thurner-Schuler, B
Stuge, TB
Paragnik, L
Kandemir, A
Lee, PP
Schuler, G
Knop, J
Enk, AH
[J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (02) : 243 - 251
[3] Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact
McIlroy, D
Gregoire, M
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2003, 52 (10) : 583 - 591
[4] Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation
Nair, S
McLaughlin, C
Weizer, A
Su, Z
Boczkowski, D
Dannull, J
Vieweg, J
Gilboa, E
[J]. JOURNAL OF IMMUNOLOGY, 2003, 171 (11) : 6275 - 6282
[5] Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells
Slingluff, CL
Petroni, GR
Yamshchikov, GV
Barnd, DL
Eastham, S
Galavotti, H
Patterson, JW
Deacon, DH
Hibbitts, S
Teates, D
Neese, PY
Grosh, WW
Chianese-Bullock, KA
Woodson, EMH
Wiernasz, CJ
Merrill, P
Gibson, J
Ross, M
Engelhard, VH
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) : 4016 - 4026

← 1 →